scaav2/8-lp1-hfixco
Gene therapyexperimental
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 22, 2010 (NCT00979238)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Coagulation factor IXSupplementation
F9 supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- scaav2/8-lp1-hfixco
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00979238 | Phase 1 | Feb 22, 2010 | Hemophilia of Georgia, Inc., National Heart, Lung, and Blood Institute (NHLBI), St. Jude Children's Hospital, University of Pennsylvania |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hemophilia of Georgia, Inc. | Academic/Hospital | 1 | 0 | 1 | 2010 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 1 | 0 | 1 | 2010 |
| St. Jude Children's Hospital | Academic/Hospital | 1 | 1 | 1 | 2010 |
| University of Pennsylvania | Academic/Hospital | 1 | 0 | 1 | 2010 |
4 organizations
Page 1 / 1